Log in
Email Address
Password
Forgot your password?
Not Registered?

Featured Tenants

 kromeknew


Kromek is pioneering digital colour imaging for x-rays and has brought ground-breaking innovation to materials technology and advanced 3D imaging, that will literally change the way in which we see the world.

Click here to learn more about Kromek

Featured Opportunity
Provision of market research response service to members of NETPark Net.

The aim of this contract is to give clients of NETPark access to a rapid response market intelligence service: swift and accurate market research which will help them identify partners, suppliers, customers and competitors. Download the documentation, which includes the specification.


For further information click here

Polls



CDEP logo

cddc   European Union emblem

Treatment hope for lupus sufferers
Bookmark and Share Add This     Email notification Email a Friend    print Printable version

Treatment hope for lupus sufferers

2008-06-09
Newsfeed

A German research team has found a possible new treatment for lupus, the chronic autoimmune disease, it has been reported.


A German research team has found a possible new treatment for lupus, the chronic autoimmune disease, it has been reported.

The proteasome inhibitor Velcade (bortezomib) is currently used to treat multiple myeloma, a cancer of the white blood cells, but scientists in Germany found that it worked against the disease and prolonged survival in mice with lupus.

"Autoantibody-mediated diseases such as autoimmune hemolytic anemia and systemic lupus erythematosus are often difficult to treat," said lead researcher Dr. Reinhard Voll, of the University of Erlangen-Nuremberg. He said that plasma cells, which are the main producers of these autoantibodies, are not effectively treated by drugs currently available.

The findings, published in Nature Medicine, were given a cautious welcome by outside experts.

"The fact that antibodies almost completely disappeared is encouraging. I look forward to hearing more about this treatment in the future," said Dr Jennifer Grossman, an assistant professor of medicine at the University of California, Los Angeles.

But another expert expressed concern that the treatment could adversely affect other cells in the human body.

"The downside is that this is a proteasome inhibitor, and there is no reason to think that it would be specific for plasma cells," Dr Noel Rose, director of the Autoimmune Disease Research Center at Johns Hopkins University, said. "It does affect other rapidly proliferating cells."

Copyright © The Press Association 2008

<http://www.nature.com/nm/index.html> (Nature Medicine)